Natacyn Suspension/ Drops
NDC Package 71776-005-15

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Natacyn (natamycin) suspension/ dropses is natamycin is used to treat fungal eye infections. This formulation utilizes a suspension/ drops delivery system. Marketed by Eyevance Pharmaceuticals, Llc, this product is identified by NDC 71776-005 and is authorized under FDA application NDA050514.

Identification & Billing

NDC Package Code
71776-005-15
Package Description
1 BOTTLE, GLASS in 1 CARTON / 15 mL in 1 BOTTLE, GLASS
Product Code
71776-005
11-Digit Billing Format
71776000515
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Natacyn
Non-Proprietary Name
Natamycin
Substance Name
Natamycin
Dosage Form
Suspension/ Drops - A suspension which is usually administered in a dropwise fashion.
Administration Route
Ophthalmic - Administration to the external eye.
Active Ingredient(s)
NATAMYCIN 50 mg/mL
Pharmacologic Class
Usage Information
Natamycin is used to treat fungal eye infections. It works by stopping the growth of certain types of fungus. This medication treats only fungal eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any drug used to treat infection can lead to its decreased effectiveness.

Regulatory & Marketing

Labeler Name
Eyevance Pharmaceuticals, Llc
Product Type
Human Prescription Drug
FDA Application #
NDA050514
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
06-12-2021
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 71776-005-15 identifies a specific commercial package of 1 bottle, glass in 1 carton / 15 ml in 1 bottle, glass of Natacyn, a human prescription drug labeled by Eyevance Pharmaceuticals, Llc. This suspension/ drops is formulated for ophthalmic use and contains natamycin as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Eyevance Pharmaceuticals, Llc on June 12, 2021. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Natamycin is used to treat fungal eye infections. It works by stopping the growth of certain types of fungus. This medication treats only fungal eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any drug used to treat infection can lead to its decreased effectiveness.

How is this Eyevance Pharmaceuticals, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 71776000515. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
71776-005-15
11-Digit CMS (5-4-2)
71776-0005-15

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.